Clinical trial
DHA (Docosahexaenoic Acid), an Omega 3 Fatty Acid, in Slowing the Progression of…
NCT00440050 · Alzheimer's Disease Cooperative Study (ADCS), Other · Completed
Key facts
| NCT number | NCT00440050 |
|---|---|
| Title | DHA (Docosahexaenoic Acid), an Omega 3 Fatty Acid, in Slowing the Progression of Alzheimer's Disease |
| Official title | A Randomized Double-Blind Placebo-Controlled Trial Of The Effects Of Docosahexaenoic Acid (DHA) In Slowing The Progression Of Alzheimer's Disease |
| Acronym | DHA |
| Lead sponsor | Alzheimer's Disease Cooperative Study (ADCS), Other |
| Collaborators | National Institute on Aging (NIA) NIH DSM Nutritional Products, Inc. Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Alzheimer's Disease |
| Intervention type | Drug |
| Interventions | DHA (Docosahexaenoic Acid), Placebo |
| Enrollment | 402 |
| Start date | Feb 1, 2007 |
| Primary completion | May 1, 2009 |
| Completion | May 1, 2009 |
| First posted | Feb 26, 2007 |
| Last update posted | Sep 25, 2014 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: